Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of post-retrograde cholangiopancreatography pancreatitis

Table 4 Pearson’s chi-squared test comparison between the three study arms’ clinical and laboratory factors at 24 h

	Control arm	Arm 1	Arm 2	Chi-square	P
Amylasemia at 24 h				11.835	0.019
< 3 × ULN	91.8%	100.0%	71.4%
> 3 × ULN	8.2%	0.0%	28.6%
Lipasemia at 24 h				9.889	0.029
< 3 × ULN	91.8%	87.5%	71.4%
> 3 × ULN	8.2%	12.5%	28.6%
CRP at 24 h				12.824	0.046
Normal	49.0%	43.8%	64.3%
Mild increase	20.4%	0.0%	7.1%
Moderate increase	22.4%	56.2%	21.4%
Severe increase	8.2%	0.0%	7.1%
Clinico-biologic status at 24 h				2.793	0.247
PEP absent	91.8%	87.5%	78.6%
PEP	8.2%	12.5%	21.4%

Arm 1: Study group A treatment regimen;

Arm 2: Study group B treatment regimen; CRP: C-reactive peptide; ULN: Upper limit of normal; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.